Literature DB >> 12679882

The effect of age on the early disposition of doxorubicin.

Jing Li1, Peter R Gwilt.   

Abstract

PURPOSE: Clinical studies indicate that anthracycline cardiotoxicity increases with patient age. This may be due to altered pharmacokinetics or pharmacodynamics. A parameter termed 'early clearance' has been shown to decrease with age in patients receiving intravenous doxorubicin. This parameter, as defined, has no immediate relationship to any physiologically based pharmacokinetic parameter. We therefore reevaluated the pharmacokinetic data to better define the relationship between doxorubicin disposition and patient age.
METHODS: Four studies provided a total of 56 patients with evaluable pharmacokinetics. The volume of the central compartment, V(c), the distribution clearance, CL(d), and total body clearance, CL, were determined for each patient and regressed against age. A physiologically based pharmacokinetic (PBPK) model for doxorubicin was also used to evaluate the effects of age on doxorubicin disposition. Published blood flows associated with various patient ages were used to simulate plasma and tissue doxorubicin concentrations. The relationship between CL(d) and initial tumor regression was also evaluated.
RESULTS: No correlation was found between V(c) and age ( P>0.05). A highly significant correlation was observed between CL(d) and age ( P<0.0005) and there was a mild but significant relationship between CL and age ( P<0.01). Use of the PBPK model with different age-related blood flows yielded virtually identical parameter values to the clinical data analyzed. Furthermore, relative tissue AUCs simulated in old and young patients compared well with those reported for daunorubicin disposition in young and old rats. In addition, a linear relationship was observed between initial tumor regression and CL(d).
CONCLUSIONS: Initial concentrations of doxorubicin following intravenous administration are higher in the elderly due to a decrease in CL(d) rather than in V(c). On the basis of simulations with the PBPK model, the reduced CL(d) appears to be related to altered regional blood flows in the elderly, and such changes may be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679882     DOI: 10.1007/s00280-002-0554-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Authors:  Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Apoptosis in Anthracycline Cardiomyopathy.

Authors:  Jianjian Shi; Eltyeb Abdelwahid; Lei Wei
Journal:  Curr Pediatr Rev       Date:  2011-11

Review 3.  Effect of age on drug metabolism in women with breast cancer.

Authors:  Jasmeet C Singh; Stuart M Lichtman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05       Impact factor: 4.481

4.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

5.  Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Authors:  Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Cardiomyocyte death in doxorubicin-induced cardiotoxicity.

Authors:  Yi-Wei Zhang; Jianjian Shi; Yuan-Jian Li; Lei Wei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-10-29       Impact factor: 4.291

7.  Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.

Authors:  Vanessa Gonzalez-Covarrubias; Jianping Zhang; James L Kalabus; Mary V Relling; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

Review 8.  Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.

Authors:  Feras Khalil; Stephanie Läer
Journal:  J Biomed Biotechnol       Date:  2011-06-01

Review 9.  Clinical pharmacology of cancer therapies in older adults.

Authors:  A Hurria; S M Lichtman
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

Review 10.  Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.

Authors:  Nina Rosa Neuendorff; Kah Poh Loh; Alice S Mims; Konstantinos Christofyllakis; Wee-Kheng Soo; Bediha Bölükbasi; Carlos Oñoro-Algar; William G Hundley; Heidi D Klepin
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.